Literature DB >> 22921929

Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test.

Michihiko Iijima1, Kenichi Fukumoto, Shigeyuki Chaki.   

Abstract

Accumulated evidence indicates that metabotropic glutamate 5 (mGlu5) receptor blockade exerts antidepressant-like and anxiolytic-like effects in several animal models. The novelty-suppressed feeding (NSF) test is used to measure anxiety-induced hypophagia in rodents. Anxiogenic-like behavior can be counteracted by acute treatment with anxiolytics or chronic treatment with antidepressants. The objective of the present study was to investigate the effect of an mGlu5 receptor antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), using the NSF test and to investigate the mechanisms underlying the effects of MPEP. The administration of MPEP at 1 h prior to testing significantly shortened the latency period until feed (an acute effect), and this effect lasted for 24 h (a sustained effect), similar to the results observed using the N-methyl-D-aspartate receptor antagonist ketamine. Pretreatment with a protein synthesis inhibitor, anisomycin, blocked the sustained, but not the acute, effects of MPEP, suggesting the involvement of new protein synthesis in the sustained effect of MPEP. In addition, the sustained effect of MPEP in the NSF test was partially abolished by pretreatment with a mammalian target of rapamycin (mTOR) antagonist, rapamycin. In contrast, a tropomyosin-related kinase, the tyrosine kinase inhibitor K252a, did not counteract the sustained effects of MPEP in this test. Taken together, these results are the first report to demonstrate that the blockade of the mGlu5 receptor exerted acute and sustained effects in the NSF test and that new protein synthesis may contribute to the sustained effects of MPEP, which may not mediate brain-derived neurotrophic factor-mTOR signaling.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22921929     DOI: 10.1016/j.bbr.2012.08.016

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  25 in total

1.  Alteration by p11 of mGluR5 localization regulates depression-like behaviors.

Authors:  K-W Lee; L Westin; J Kim; J C Chang; Y-S Oh; B Amreen; J Gresack; M Flajolet; D Kim; A Aperia; Y Kim; P Greengard
Journal:  Mol Psychiatry       Date:  2015-09-15       Impact factor: 15.992

Review 2.  Metabotropic Glutamate Receptor 5 as a Target for the Treatment of Depression and Smoking: Robust Preclinical Data but Inconclusive Clinical Efficacy.

Authors:  Samuel A Barnes; Douglas J Sheffler; Svetlana Semenova; Nicholas D P Cosford; Anton Bespalov
Journal:  Biol Psychiatry       Date:  2018-03-09       Impact factor: 13.382

3.  Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test.

Authors:  Kenichi Fukumoto; Michihiko Iijima; Shigeyuki Chaki
Journal:  Psychopharmacology (Berl)       Date:  2014-01-09       Impact factor: 4.530

4.  cGMP-dependent protein kinase type II knockout mice exhibit working memory impairments, decreased repetitive behavior, and increased anxiety-like traits.

Authors:  Charlotte M Wincott; Sinedu Abera; Sarah A Vunck; Natasha Tirko; Yoon Choi; Roseann F Titcombe; Shannon O Antoine; David S Tukey; Loren M DeVito; Franz Hofmann; Charles A Hoeffer; Edward B Ziff
Journal:  Neurobiol Learn Mem       Date:  2014-04-18       Impact factor: 2.877

5.  Ketamine Alleviates Fear Generalization Through GluN2B-BDNF Signaling in Mice.

Authors:  Muhammad Asim; Bo Hao; Yu-Han Yang; Bu-Fang Fan; Li Xue; Yan-Wei Shi; Xiao-Guang Wang; Hu Zhao
Journal:  Neurosci Bull       Date:  2019-08-23       Impact factor: 5.203

Review 6.  Convergent Mechanisms Underlying Rapid Antidepressant Action.

Authors:  Panos Zanos; Scott M Thompson; Ronald S Duman; Carlos A Zarate; Todd D Gould
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

7.  Antidepressant activity of phytochemicals of Mangifera indica seeds assisted by integrated computational analysis.

Authors:  Uzma Saleem; Shafa Iman; Bashir Ahmad; Muhammad Ajmal Shah; Shabana Bibi; Mohammed Alqarni; Muhammad Saad Khan; Ghulam Mujtaba Shah; Haroon Khan; Reem Hasaballah Alhasani; Norah A Althobaiti; Aishah E Albalawi
Journal:  Metab Brain Dis       Date:  2022-03-28       Impact factor: 3.584

8.  Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression.

Authors:  Anthony J Hannan; Thibault Renoir; Volkan Uzungil; Harvey Tran; Connor Aitken; Carey Wilson; Carlos M Opazo; Shanshan Li; Jennyfer M Payet; Celeste H Mawal; Ashley I Bush; Matthew W Hale
Journal:  Neurotherapeutics       Date:  2022-07-21       Impact factor: 6.088

9.  Rapamycin blocks the antidepressant effect of ketamine in task-dependent manner.

Authors:  Kristina Holubova; Lenka Kleteckova; Martina Skurlova; Jan Ricny; Ales Stuchlik; Karel Vales
Journal:  Psychopharmacology (Berl)       Date:  2016-03-23       Impact factor: 4.530

10.  BDNF-ERK-CREB signalling mediates the role of miR-132 in the regulation of the effects of oleanolic acid in male mice.

Authors:  Li-Tao Yi; Jing Li; Bin-Bin Liu; Liu Luo; Qing Liu; Di Geng
Journal:  J Psychiatry Neurosci       Date:  2014-09       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.